The hot competition in biotechnology, where scientists race to cure complex diseases, boiled over last week as a company seeking to treat a deadly muscle disorder made an unusual move: It publicly criticized a rival's data. All BioMarin Pharmaceuticals Inc. of San Rafael, Calif., did was show investors two slides to illustrate an argument that its trial results were superior to those of Sarepta Therapeutics Inc. of Cambridge, Mass.